Olmesartan Medoxomilo + Hidroclorotiazida Viatris (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil is an angiotensin II receptor blocker that selectively inhibits AT‑1 receptors, preventing angiotensin‑II‑mediated vasoconstriction and aldosterone secretion. This leads to relaxation of blood vessels and reduced sodium‑water retention, helping to lower systemic blood pressure.

The appropriate dose is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and overall clinical profile. Dosage adjustments are made according to therapeutic response and tolerability, following local prescribing guidelines.

Olmesartan Medoxomilo + Hidroclorotiazida is contraindicated in pregnancy, particularly in the second and third trimesters, because it can cause fetal toxicity. Breastfeeding is not recommended unless the benefits outweigh potential risks, and this decision should be made by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy using either an ARB or a thiazide diuretic, the olmesartan‑hydrochlorothiazide combo offers additive blood‑pressure reduction, often achieving target levels with a single tablet. It may be preferred over separate pills for adherence, but clinicians consider individual patient factors when selecting alternatives such as ACE‑inhibitor‑diuretic combos or calcium‑channel blocker‑based regimens.

Store the tablets at temperatures below 25 °C in their original container, protecting them from moisture, heat and direct sunlight. Do not refrigerate or freeze the product.

The medication is taken orally, usually once daily, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether the tablet should be swallowed whole or can be divided, if permitted.

Serious adverse events include severe hypotension, acute kidney injury, hyper‑kalemia, angio‑edema and liver function abnormalities. Patients should seek immediate medical attention if they experience symptoms such as sudden dizziness, swelling of the face or throat, or marked changes in urine output.

The product should be avoided in patients with known hypersensitivity to olmesartan, hydrochlorothiazide or any excipients, in pregnant women, and in individuals with severe renal impairment or electrolyte disturbances that could be worsened by a thiazide diuretic.